Mink Therapeutics, INC. (INKT) — 10-Q Filings

10-Q Filings (6)

• MiNK Therapeutics' Losses Widen Amidst Equity Raise, Going Concern Doubts — Nov 14, 2025 Risk: high
  MiNK Therapeutics, Inc. (INKT) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $9,892,157, up from $8,321,698
• MiNK Therapeutics' Cash Dwindles Amid Rising Losses, Reverse Split — Aug 14, 2025 Risk: high
  MiNK Therapeutics, Inc. (INKT) reported a net loss of $7.00 million for the six months ended June 30, 2025, an increase from a net loss of $6.52 million in the
• MiNK Therapeutics Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  MiNK Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results and provided updates on its operations. Key
• MiNK Therapeutics Reports Q3 2024 Equity Changes, Agenus Agreement — Nov 14, 2024 Risk: medium
  MiNK Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported changes in its equity accounts, including an increase in A
• MiNK Therapeutics Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
  MiNK Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported research and development expenses related to Atlant Clinical Lt
• MiNK Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: medium
  MiNK Therapeutics, Inc. (INKT) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. MiNK Therapeutics, Inc. filed a 10-Q for the quarter ended March 31

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX